Biogen and Denali Discontinue Parkinson's Drug BIIB122 After Phase 2b Failure

What happened

Biogen and Denali Therapeutics announced that the Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson's disease failed to meet its primary endpoint of slowing disease progression versus placebo, with no benefit observed on secondary endpoints. Despite achieving >90% peripheral LRRK2 kinase inhibition and expected drug levels in blood and CSF, the biomarker reduction of phosphorylated Rab10 was only ~30%, and clinical efficacy did not follow. As a result, development in idiopathic Parkinson's disease is stopped, though Denali will continue a Phase 2a study in LRRK2 variant carriers. This outcome is a setback for Biogen's pipeline diversification but has limited near-term financial impact given BIIB122 was an early-stage asset with no approved revenue contribution. The failure underscores the high risk of CNS drug development and the challenge of translating strong target engagement into clinical benefit, particularly in Parkinson's where prior LRRK2 inhibitors have also struggled.

Implication

The BIIB122 failure removes a potential mid-term catalyst and highlights the inherent risk in Biogen's pipeline strategy, which relies heavily on business development and early-stage assets. While the drug was not a near-term revenue driver, its discontinuation adds to the narrative that Biogen's pipeline outside of Leqembi and Skyclarys is unproven. Near-term focus remains on 2026 guidance and Leqembi adoption; this news may cause minor negative sentiment but does not change the fundamental thesis. Investors should monitor for additional pipeline setbacks that could further pressure the stock toward the $160 bear case.

Thesis delta

The BIIB122 Phase 2b failure removes a marginal upside option in Parkinson's and reinforces the thesis that Biogen's pipeline carries significant binary risk. The core investment case still hinges on Leqembi scaling and rare-disease growth offsetting MS decline, but this setback slightly reduces confidence in pipeline-derived upside beyond 2026. The WAIT rating remains appropriate; investors should look for clearer proof of growth from existing launches before adding exposure.